GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lyka Labs Ltd (BOM:500259) » Definitions » Shiller PE Ratio

Lyka Labs (BOM:500259) Shiller PE Ratio : (As of Jun. 10, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Lyka Labs Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Lyka Labs Shiller PE Ratio Historical Data

The historical data trend for Lyka Labs's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lyka Labs Shiller PE Ratio Chart

Lyka Labs Annual Data
Trend Jun14 Jun15 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lyka Labs Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lyka Labs's Shiller PE Ratio

For the Biotechnology subindustry, Lyka Labs's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lyka Labs's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lyka Labs's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Lyka Labs's Shiller PE Ratio falls into.



Lyka Labs Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Lyka Labs's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Lyka Labs's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.6/153.0345*153.0345
=-0.600

Current CPI (Mar. 2024) = 153.0345.

Lyka Labs Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201209 0.190 82.244 0.354
201212 2.490 83.774 4.549
201303 -3.449 85.687 -6.160
201306 -1.140 88.365 -1.974
201309 -1.400 91.042 -2.353
201312 -4.420 91.425 -7.399
201406 3.906 94.103 6.352
201412 -2.740 96.780 -4.333
201506 -2.340 99.841 -3.587
201512 0.230 102.901 0.342
201603 -4.750 102.518 -7.091
201606 -1.890 105.961 -2.730
201609 0.210 105.961 0.303
201612 -1.320 105.196 -1.920
201703 0.820 105.196 1.193
201803 -6.710 109.786 -9.353
201806 -1.790 111.317 -2.461
201809 -2.300 115.142 -3.057
201812 -0.670 115.142 -0.890
201903 2.270 118.202 2.939
201906 -1.130 120.880 -1.431
201909 -1.140 123.175 -1.416
201912 -14.500 126.235 -17.578
202003 -4.530 124.705 -5.559
202006 -1.640 127.000 -1.976
202009 -2.010 130.118 -2.364
202012 -0.800 130.889 -0.935
202103 0.380 131.771 0.441
202106 6.800 134.084 7.761
202109 9.900 135.847 11.153
202112 2.110 138.161 2.337
202203 -5.260 138.822 -5.799
202206 0.200 142.347 0.215
202209 -0.140 144.661 -0.148
202212 -3.640 145.763 -3.822
202303 -1.040 146.865 -1.084
202306 -0.570 150.280 -0.580
202309 -0.160 151.492 -0.162
202312 0.530 152.924 0.530
202403 -0.600 153.035 -0.600

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Lyka Labs  (BOM:500259) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Lyka Labs Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Lyka Labs's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lyka Labs (BOM:500259) Business Description

Traded in Other Exchanges
Address
30, Forjett Street, Near Bhatia Hospital, Ground floor, Spencer Building (Block B & C), Grant Road (West), Mumbai, MH, IND, 400036
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment viz. pharmaceuticals. The Company has presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.

Lyka Labs (BOM:500259) Headlines

No Headlines